Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Augustin

Showing results (461-470 of 491) with videos related to

Pageof 50
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 31, 2023
S3 guideline Atopic dermatitis: Part 2 - Systemic treatmentThomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
International Journal of Dermatology|January 29, 2025
Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External ExpertsPavel V Chernyshov, Andrew Y Finlay, Lucia Tomas-Aragones, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 3, 2024
S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groupsThomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
Dermatology (Basel, Switzerland)|January 12, 2017
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTTJulia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 5, 2024
Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in GermanyMarcus Maurer, Matthias Augustin, Sabine Bauer, et al.
BMJ Open|July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocolMatthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
International Journal of Dermatology|July 21, 2025
Quality of Life Measurement in Autoimmune Blistering Diseases: Mutual Position Statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Autoimmune Blistering DiseasesPavel V Chernyshov, Andrew Y Finlay, Aikaterini Patsatsi, et al.
Skin Health and Disease|November 28, 2025
Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermanyLuise Heinrich, Thomas Birkner, Susanne Abraham, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2026
S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoringAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
Pageof 50

Showing results (461-470 of 491) with videos related to

Sort By:
Pageof 50
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 31, 2023
S3 guideline Atopic dermatitis: Part 2 - Systemic treatmentThomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
International Journal of Dermatology|January 29, 2025
Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External ExpertsPavel V Chernyshov, Andrew Y Finlay, Lucia Tomas-Aragones, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 3, 2024
S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groupsThomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
Dermatology (Basel, Switzerland)|January 12, 2017
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTTJulia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 5, 2024
Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in GermanyMarcus Maurer, Matthias Augustin, Sabine Bauer, et al.
BMJ Open|July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocolMatthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
International Journal of Dermatology|July 21, 2025
Quality of Life Measurement in Autoimmune Blistering Diseases: Mutual Position Statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Autoimmune Blistering DiseasesPavel V Chernyshov, Andrew Y Finlay, Aikaterini Patsatsi, et al.
Skin Health and Disease|November 28, 2025
Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermanyLuise Heinrich, Thomas Birkner, Susanne Abraham, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2026
S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoringAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
Pageof 50